玻璃体腔内植入装置在玻璃体视网膜疾病中的临床应用  

Clinical Application of Intravitreal Implantation Device in Vitreoretinal Diseases

作　　者：郑甄甄 吴谦 ZHENG Zhenzhen;WU Qian(Department of Ophthalmology,Affiliated Hospital of Putian University,Putian Fujian 351100,China)

机构地区：[1]莆田学院附属医院眼科,福建莆田351100

出　　处：《中国卫生标准管理》2023年第21期100-103,共4页China Health Standard Management

摘　　要：目的 观察玻璃体视网膜疾病采取玻璃体腔内植入装置的应用效果。方法 选取2022年4月—2023年4月莆田学院附属医院眼科71例玻璃体视网膜疾病患者资料,按照随机数字表法分为对照组(35例)与观察组(36例)。对照组实施黄斑激光光凝治疗,观察组实施玻璃体腔内注射地塞米松玻璃体内植入剂(DEX)治疗。比较两组治疗效果、满意度、最佳矫正视力(best corrected vision,BCVA)、黄斑中心凹厚度(central macular thickness,CMT)、眼压、搏动指数(pulsatility index,PI)、血流阻力(resistance,RI)指标。结果 观察组治疗效果及满意度情况优于对照组(P <0.05)。两组治疗前BCVA、CMT比较,差异无统计学意义(P> 0.05);治疗后1周及1、3个月后,观察组BCVA、CMT优于对照组(P <0.05)。治疗前,两组眼压、PI、RI比较,差异无统计学意义(P> 0.05);治疗后,两组眼压变化比较,差异无统计学意义(P> 0.05),观察组PI、RI优于对照组(P <0.05)。结论 在玻璃体视网膜疾病患者中,给予玻璃体腔内植入装置,完成治疗工作,能够有效促进患者视力恢复,提升患者治疗效果,并且不会增加患者眼压。Objective To observe the application effect of intravitreal implantation devices in vitreoretinal diseases.Methods A total of 71 patients with vitreoretinal diseases from the department of ophthalmology,Affiliated Hospital of Putian University from April 2022 to April 2023,and divide them into a control group(35 cases)and an observation group(36 cases)using a random number table method.The control group received macular laser photocoagulation treatment,while the observation group received intravitreal injection of dexamethasone intravitreal implant(DEX)treatment.The treatment efficacy,satisfaction,best corrected vision(BCVA),central macular thickness(CMT),intraocular pressure,pulsatility index(PI),and blood flow resistance(RI)indicators of the two groups were compered.Results The treatment effect and satisfaction of the observation group were better than those in the control group(P<0.05).There was no significant difference between BCVA and CMT before treatment(P>0.05);and BCVA and CMT in the observation group were better than those in the control group,after 1 week,1 month and 3 months after treatment.Before treatment(P<0.05),there was no significant difference in intraocular pressure,PI and RI between the two groups(P>0.05);and after treatment,there was no significant difference in intraocular pressure changes between the two groups(P>0.05);and PI and RI in the observation group were better than those in the control group(P<0.05).Conclusion In patients with vitreoretinal diseases,implantation of devices into the vitreous cavity can effectively promote visual recovery,improve treatment effectiveness,and do not increase intraocular pressure.

关 键 词：玻璃体腔内植入装置 玻璃体视网膜疾病 黄斑激光光凝 地塞米松 BCVA 治疗效果 

分 类 号：R774[医药卫生—眼科]